Table 2.

Metabolic characteristics of the primary tumor according to the clinical, biologic, and pathologic status

Baseline SUVmaxΔSUVmax
nMean ± SDPanMean (%) ± SDPa
All patients5013.4 ± 7.644−43.7 ± 25.4
Inflammatory breast cancer0.04NS
 No4613.0 ± 7.340−44.7 ± 23.3
 Yes322.2 ± 7.73−52.3 ± 32.6
Tumor grading (SBR)0.003NS
 Score II77.3 ± 3.56−33.7 ± 12.3
 Score III3914.8 ± 7.534−45.5 ± 27.0
Architectural differentiation0.03NS
 Score II79.3 ± 3.07−40.2 ± 22.3
 Score III3814.7 ± 7.733−44.4 ± 26.5
Ki-67 expressionNS0.020
 ≤50%1111.7 ± 6.68−23.4 ± 23.0
 >50%3213.9 ± 6.429−47.2 ± 25.3
EGFR expressionNSNS
 Negative2613.7 ± 7.424−46.8 ± 25.5
 Positive2013.4 ± 8.616−35.6 ± 24.4
CK5/6 expression0.06NS
 Negative1210.3 ± 6.912−41.9 ± 19.6
 Positive3414.7 ± 8.028−42.5 ± 27.8
AR status0.09NS
 Negative (<10%)3814.3 ± 8.033−44.5 ± 26.2
 Positive89.9 ± 6.67−31.7 ± 18.6
PhenotypeNSNS
 Basal-like3914.1 ± 7.733−42.2 ± 26.3
 Non–basal-like710.5 ± 8.87−42.8 ± 21.8
Chemotherapy regimenNSNS
 Continuous (FEC100)913.9 ± 5.99−54.7 ± 22.1
 Sequential (FEC100 + taxotere)4113.3 ± 8.035−40.8 ± 25.8
SurgeryNS0.03
 Breast-conserving surgery3714.1 ± 7.833−48.5 ± 23.0
 Mastectomy1311.4 ± 7.011−29.0 ± 27.8

NOTE: Age (cutoff, 50 years), menopausal status, tumor size (cutoff, 5 cm), nuclear pleomorphism, number of mitoses, phenotype (basal vs. nonbasal), CA15.3, ACE, and CA-125 values were not significantly correlated with tumor metabolic characteristics. Bold numerals correspond to statistically significant P values (<0.05).

Abbreviation: NS, not significant (P < 0.1).

  • aMann–Whitney test.